Susan Spitz

Incyte (United States) — United States

Medicine · Health Sciences

14h-index897citations38works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(13), Monoclonal and Polyclonal Antibodies Research(8), Biosimilars and Bioanalytical Methods(8), Advanced Breast Cancer Therapies(8), Advanced Biosensing Techniques and Applications(5)

Publications38 total

Circulating tumor DNA concentrations and blood tumor mutation burden as biomarkers of outcomes in a phase 1 study of select advanced solid tumors.
Journal of Clinical Oncology·2025
A phase 1 study of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors: Updated safety, efficacy, and pharmacokinetics (PK) results.
Journal of Clinical Oncology·2024
155P A phase I study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors
Immuno-Oncology Technology·2023Open Access
Supplementary Table from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
2023Open Access
Data from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
2023Open Access
Supplementary Figure from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
2023Open Access
Supplementary Data from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
2023Open Access
Data from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
2023Open Access
Supplementary Data from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
2023Open Access
Supplementary Table from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
2023Open Access
Supplementary Table from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
2023Open Access
Supplementary Figure from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
2023· 1 citedOpen Access
Supplementary Table from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
2023Open Access
2020 White Paper on Recent Issues in Bioanalysis: BAV Guidance, CLSI H62, Biotherapeutics Stability, Parallelism Testing, CyTOF and Regulatory Feedback ( <u>Part 2A</u> –Recommendations on Biotherapeutics Stability, PK LBA Regulated Bioanalysis, Biomarkers Assays, Cytometry Validation &amp; Innovation <u>Part 2B</u> –Regulatory Agencies’ Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene &amp; Cell Therapy and Vaccine)
Bioanalysis·2021· 24 cited
A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity
Frontiers in Oncology·2020· 41 citedOpen Access
419 Pharmacodynamic biomarkers demonstrate T-cell activation in patients treated with the oral PD-L1 inhibitor INCB086550 in a phase 1 clinical trial
Regular and Young Investigator Award Abstracts·2020· 3 citedOpen Access
2019 White Paper on Recent Issues in Bioanalysis: Chromatographic Assays (Part 1 – Innovation in Small Molecules and Oligonucleotides &amp; Mass Spectrometric Method Development Strategies for Large Molecule Bioanalysis)
Bioanalysis·2019· 39 citedOpen Access
2018 White Paper on Recent Issues in Bioanalysis: Focus on Immunogenicity Assays by Hybrid LBA/LCMS and Regulatory Feedback (Part 2 – PK, PD &amp; ADA Assays by Hybrid LBA/LCMS &amp; Regulatory Agencies’ Inputs on Bioanalysis, Biomarkers and Immunogenicity)
Bioanalysis·2018· 37 citedOpen Access
2016 White Paper on Recent Issues in Bioanalysis: Focus on Biomarker Assay Validation (BAV): (Part 2 – Hybrid LBA/LCMS and Input from Regulatory Agencies)
Bioanalysis·2016· 42 citedOpen Access
2015 White Paper on Recent Issues in Bioanalysis: Focus on New Technologies and Biomarkers (Part 2 – Hybrid LBA/LCMS and Input from Regulatory Agencies)
Bioanalysis·2015· 55 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Jonathan Rios‐Doria(12), Nina Zolotarjova(11), Gregory Hollis(11), Christina Stevens(11), Maryanne Covington(11), Peggy Scherle(11), Holly K. Koblish(11), Kevin O’Hayer(11), Ryan Geschwindt(11), Liangxing Wu(10), Liang‐Chuan S. Wang(10), Phillip C.C. Liu(10), Robert Wynn(10), Alla Volgina(10), Kanishk Kapilashrami(10), Elham Behshad(10), Yan‐ou Yang(10), Sharon Diamond(10), Maxim Soloviev(10), Stephen C. Rubin(10)